TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1556522
Drug: Evening insulin
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Evening insulin therapy
Study: 29545530
Drug: Morphine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine infusion as PCIA (morphine group)
Study: 26810403
Drug: Ingenol mebutate
Normalized name: Ingenol Mebutate
DrugBank: Ingenol mebutate (DB05013)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ingenol mebutate (IngMeb) 0.015% daily for 3 days followed by clobetasol propionate (0.05%) twice daily for 4 days
Study: 26810403
Drug: Ingenol mebutate
Normalized name: Ingenol Mebutate
DrugBank: Ingenol mebutate (DB05013)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ingenol mebutate (IngMeb) 0.015% daily for 3 days
Study: 22270198
Drug: DCN and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCN and vehicle (initial treatment)
Study: 17928105
Drug: Citalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (20 mg/day) plus placebo
Study: 17928105
Drug: Citalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (20 mg/day) plus pindolol (7.5 mg/day)
Study: 12776276
Drug: Intravenous vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vitamin C, 500 mg, three times a week
Study: 6148617
Drug: Intravenous followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous followed by oral propranolol
Study: 26977625
Drug: Venlafaxine (75-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine (75-150 mg/day for 4 weeks)
Study: 26977625
Drug: Venlafaxine (75-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine (75-150 mg/day for 4 weeks) plus cerebrolysin (20 i/v infusions during 4 weeks, 20.0 ml in 100 ml isotonic NaCl solution)
Study: 22432114
Drug: Fenofibrate therapy
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fenofibrate therapy (case subjects, n = 321)
Study: 12297844
Drug: 3 MU
Normalized name: Orasep Reformulated Dec 2013 Mucosal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 MU IFN alfa‐2b 3 times per week plus ribavirin 1,000 mg/d for 12 months (Group A)
Study: 2552600
Drug: Nedocromil sodium,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nedocromil sodium, 4 mg four times daily by inhalation
Study: 1091305
Drug: Electrosleep (ES)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrosleep (ES) treatment; five half-hour sessions; duration not specified.
Study: 21874260
Drug: BCAA (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA (12 g/day)
Study: 31169723
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (C group) with 5 small round patches of adhesive pads positioned bilaterally at the same points.
Study: 29275795
Drug: Classical acupuncture
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Classical acupuncture with placebo tablet
Study: 29275795
Drug: Sham acupuncture
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham acupuncture with placebo tablet
Study: 29275795
Drug: Sham acupuncture
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham acupuncture with ibuprofen
Study: 21925346
Drug: pantethine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: pantethine (600 mg/d for weeks 1-8, then 900 mg/d for weeks 9-16)
Study: 12806269
Drug: Antidepressants (SSRIs)
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants (SSRIs)
Study: 16773951
Drug: Antidepressants (non-specific)
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants (non-specific)
Study: 12957419
Drug: Aspirin (325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (325 mg/day for four weeks)
Study: 25855628
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg prednisone daily for 5 days
Study: 25855628
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg prednisone daily for 14 days
Study: 25855628
Drug: Prednisone treatment
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone treatment (both 5 and 14 days)
Study: 18078906
Drug: Contrast material
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast material containing 300 mg iodine/mL (Iomeprol 300) injected at a rate of 1 g of iodine/second
Study: 18078906
Drug: Contrast material
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast material containing 400 mg iodine/mL (Iomeprol 400) injected at a rate of 1 g of iodine/second
Study: 16610157
Drug: Internet-based cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive-behavioral therapy (n = 26)
Study: 12826971
Drug: Fentanyl (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (2 microg/kg intravenous)
Study: 11596665
Drug: Perindopril-indapamide combination
Normalized name: indapamide / perindopril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril-indapamide combination (ACE inhibitor-diuretic)
Study: 11596665
Drug: Usual guidelines-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual guidelines-based therapy for glucose control
Study: 8285750
Drug: Milk feeds
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk feeds supplemented with Lactobacillus GG 10(8) colony forming units twice a day for two weeks
Study: 3578848
Drug: 0.02% morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.02% morphine
Study: 3578848
Drug: Saline (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (30 ml perineurally and 1 ml intramuscularly) with 6 mg morphine
Study: 30123060
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C and E supplementation (2000 mg/d vitamin C; 1400 U/d vitamin E)
Study: 27062334
Drug: Guideline-concordant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-concordant therapy
Study: 27062334
Drug: Empiric therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empiric therapy (sulbactam/ampicillin or ceftriaxone)
Study: 25023798
Drug: Meloxicam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam (1 mg/kg of BW) administered orally at loading (d 0), unloading (d 1), and daily from d 2 to 7 of feedlot receiving (MEL)
Study: 25023798
Drug: Lactose monohydrate
Normalized name: Lactose Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose monohydrate (1 mg/kg of BW) administered orally (TRANS)
Study: 25023798
Drug: Lactose monohydrate
Normalized name: Lactose Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose monohydrate (1 mg/kg of BW) administered orally (CON)
Study: 25023798
Drug: Meloxicam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam (1 mg/kg of BW) administered orally (MEL)
Study: 23467862
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A injections prior to cast treatment
Study: 23467862
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (cast treatment and botulinum toxin A)
Study: 18572334
Drug: Alendronate 20
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate 20 mg once weekly
Study: 12694145
Drug: Rectal paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal paracetamol 1000 mg four times daily
Study: 12694145
Drug: Rectal paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal paracetamol 1000 mg
Study: 12694145
Drug: Higher paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher paracetamol concentration
Study: 10894579
Drug: Digital rectal
Normalized name: BD Thermometer Digital Rectal (obsolete)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital rectal examination (DRE) in patients with AMI (Group I)
Study: 10894579
Drug: Digital rectal
Normalized name: BD Thermometer Digital Rectal (obsolete)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital rectal examination (DRE) in patients without AMI (Group III)
Study: 3812055
Drug: Physician advice
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Physician advice plus nicotine chewing gum (NCG) prescription
Study: 22170177
Drug: Magnesium infusion
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium infusion within 4 days (Group I)
Study: 10732143
Drug: LH (Luteinizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: LH (Luteinizing Hormone)
Study: 10732143
Drug: FSH (Follicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: FSH (Follicle Stimulating Hormone)
Study: 7496933
Drug: Acetaminophen (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (1,000 mg every 6 h for 2 days)
Study: 2683263
Drug: Cyclosporine (CsA)
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (CsA) 10 mg/kg/day and prednisone
Study: 890617
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of prophylactic systemic antibiotics in high-risk patients
Study: 31943807
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (NAPLS2)
Study: 26895652
Drug: Dynamic light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic light application (DLA) therapy, administered through ceiling-mounted fluorescent tubes delivering bluish-white light up to 1700 lux between 0900 h and 1600 h, except for 1130-1330 h when dimmed to 300 lux.
Study: 24388379
Drug: Ketotifen 0.025%
Normalized name: KETOTIFEN 0.025% OPH SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen 0.025% ophthalmic solution, one drop twice daily for 28 days
Study: 24388379
Drug: Olopatadine 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olopatadine 0.1% ophthalmic solution, one drop twice daily for 28 days
Study: 18376350
Drug: Incretin effect
Normalized name: Secretin
DrugBank: Secretin human (DB09532)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Incretin effect calculated using insulin responses
Study: 15649722
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg acetylsalicylic acid (ASA)
Study: 12165118
Drug: DITPA 1.875
Approvals — FDA: no, EMA: no, PMDA: no
Description: DITPA 1.875 mg/kg daily for 2 weeks, then 3.75 mg/kg daily for 2 weeks
Study: 10442508
Drug: Ginger rhizome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger rhizome extract (2 x 100 mg)
Study: 580623
Drug: Propylthiouracil, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propylthiouracil, 150 mg every eight hours
Study: 580623
Drug: Propylthiouracil, 450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propylthiouracil, 450 mg as a single daily dose
Study: 580623
Drug: Switching to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching to propylthiouracil, 150 mg every eight hours after initial failure
Study: 28913846
Drug: Pomegranate juice
Normalized name: pomegranate juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate juice (220 mL daily for 5 days)
Study: 28913846
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (conventional medical therapies only)
Study: 9392401
Drug: Ceftriaxone, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone, 50 mg/kg (single i.m. injection, with a second dose if unsatisfactory response after 48 h)
Study: 9392401
Drug: Amoxicillin clavulanate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin clavulanate, 12.5 mg tid (10-day course)
Study: 7930480
Drug: Nicardipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (20 mg orally; n = 8)
Study: 28926120
Drug: Glecaprevir/pibrentasvir (G/P)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glecaprevir/pibrentasvir (G/P) for 12 weeks
Study: 28926120
Drug: Glecaprevir/pibrentasvir (G/P)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glecaprevir/pibrentasvir (G/P) for 16 weeks
Study: 19114761
Drug: Morphine and
Normalized name: morphine and antispasmodics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine and Ketorolac administered 1 hr prior to skin incision
Study: 19114761
Drug: Morphine and
Normalized name: morphine and antispasmodics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine and Ketorolac administered at peritoneum closure
Study: 16488321
Drug: Etanercept 50
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 50 mg subcutaneous weekly
Study: 8678775
Drug: Cefotaxime sodium
Normalized name: Cefotaxime Sodium
DrugBank: Cefotaxime (DB00493)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefotaxime sodium (1 g)
Study: 8678775
Drug: Ticarcillin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticarcillin plus clavulanic acid (3.1 g)
Study: 8678775
Drug: Ceftriaxone sodium
Normalized name: Ceftriaxone Sodium
DrugBank: Ceftriaxone (DB01212)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftriaxone sodium (1 g)
Study: 30357332
Drug: G1P[8] rotavirus
Approvals — FDA: no, EMA: no, PMDA: no
Description: G1P[8] rotavirus vaccine (2-3 doses)
Study: 30156433
Drug: Contingency management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contingency management for other drug
Study: 24715424
Drug: Oligofructose (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oligofructose (30 g day(-1) for 6 weeks)
Study: 22244522
Drug: Trabeculectomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabeculectomy with mitomycin C (MMC 0.4 mg/mL for 4 minutes)
Study: 20807969
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (social intervention + antidepressants)
Study: 14693573
Drug: ADP receptor
Normalized name: ADP-597
DrugBank: ADP-597 (DB12084)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADP receptor antagonist alone
Study: 14693573
Drug: ADP receptor
Normalized name: ADP-597
DrugBank: ADP-597 (DB12084)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADP receptor antagonist plus IV heparin
Study: 11964722
Drug: Dietary antioxidants;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary antioxidants; specific dosage and duration not available
Study: 9721148
Drug: Budesonide enema
Normalized name: budesonide Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide enema 2.0 mg/100 mL
Study: 9721148
Drug: Budesonide enema
Normalized name: budesonide Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide enema 8.0 mg/100 mL
Study: 9721148
Drug: Budesonide enema
Normalized name: budesonide Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide enema (both doses)
Study: 3056816
Drug: Biosynthetic human
Normalized name: Proinsulin biosynthetic human
DrugBank: Proinsulin human (DB17875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biosynthetic human proinsulin (assumed potency 4 U/mg)
Study: 219500
Drug: Antacid mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid mixture plus sulpiride
Study: 219500
Drug: Antacid mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid mixture alone
Study: 27838576
Drug: Snapshot‐Freeze (SSF)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Snapshot‐Freeze (SSF) with beta-blockers (BB)
Study: 27838576
Drug: Snapshot‐Freeze (SSF)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Snapshot‐Freeze (SSF) without beta-blockers (non-BB)
Study: 27838576
Drug: Standard reconstruction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard reconstruction (STD) with beta-blockers (BB)
Study: 27838576
Drug: Standard reconstruction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard reconstruction (STD) without beta-blockers (non-BB)
Study: 15180019
Drug: Midazolam (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (starting dose of 0.1 mg/kg/h)
Study: 15180019
Drug: Dexmedetomidine (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (starting dose of 0.25 microg/kg/h)
Study: 15180019
Drug: Dexmedetomidine (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (starting dose of 0.5 microg/kg/h)
Study: 7817169
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no heparin prophylaxis)
Study: 3043128
Drug: Cytoprotective antacidum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoprotective antacidum (226 mval acid‐neutralisation‐capacity per day's dose)
Study: 3043128
Drug: Cimetidine (2x
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (2x 400 mg)
Study: 3043128
Drug: Initial combination
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial combination treatment of antacidum with Cimetidine for 1 week, followed by antacidum
Study: 28336937
Drug: FCM-miniR (mitoxantrone
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCM-miniR (mitoxantrone with low-dose rituximab)
Study: 19329405
Drug: High-dose multivitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose multivitamin and mineral supplement (MMS)
Study: 19329405
Drug: Low-dose MMS
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose MMS
Study: 16394956
Drug: Antioxidants (AO)
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidants (AO) - 1000 mg vitamin C and 300 mg RRR‐alpha‐tocopheryl acetate
Study: 11345029
Drug: Ukrain 50
Normalized name: Ukrain cation
DrugBank: Ukrain cation (DB17150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ukrain 50 mg (5 mg every second day for a total of 10 injections)
Study: 11345029
Drug: Ukrain 100
Normalized name: Ukrain cation
DrugBank: Ukrain cation (DB17150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ukrain 100 mg (10 mg injections)
Study: 11345029
Drug: Symptomatic corrective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic corrective therapy (control group)
Study: 1622919
Drug: Erythromycin, 500
Normalized name: Erythromycin, 500 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin, 500 mg twice a day for 7 1/2 days starting the evening before the abortion
Study: 6691563
Drug: Cimetidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (300 mg orally with a sip of water 1‐4 hr before induction)
Study: 6691563
Drug: Cimetidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (300 mg orally with a sip of water 1‐4 hr before induction) + Glycopyrrolate (4‐5 micrograms/kg intramuscularly 45‐90 min before induction)
Study: 30021588
Drug: Best current
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best current treatment plus ultrasound-guided intra-articular hip injection of corticosteroid (triamcinolone acetonide 40 mg) with 1% lidocaine hydrochloride
Study: 30021588
Drug: Best current
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best current treatment plus ultrasound-guided intra-articular hip injection of 1% lidocaine hydrochloride alone
Study: 30021588
Drug: Best current
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best current treatment alone
Study: 18338275
Drug: 3‐in‐1 block
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3‐in‐1 block with 40 ml of 0.25% bupivacaine 30‐minutes before surgery
Study: 7574952
Drug: High-dose aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose aprotinin according to the 'Hammersmith' regimen
Study: 2117207
Drug: Inositol (INO)
Normalized name: Inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inositol (INO) supplementation (70‐100 mg/kg/day)
Study: 21495829
Drug: bisoprolol/hydrochlorothiazide 5/6.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: bisoprolol/hydrochlorothiazide 5/6.25 mg
Study: 21495829
Drug: amlodipine/valsartan 5/160
Approvals — FDA: no, EMA: no, PMDA: no
Description: amlodipine/valsartan 5/160 mg
Study: 15323587
Drug: Quetiapine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (300 mg/day, titrated upward)
Study: 9875113
Drug: Intracoronary GTN
Normalized name: GTN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary GTN (0.2 mg)
Study: 9875113
Drug: ISDN spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISDN spray (0.8 mg)
Study: 9875113
Drug: Sublingual GTN
Normalized name: GTN Sublingual Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual GTN capsule (0.8 mg)
Study: 9054791
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy (graded activity and cognitive restructuring)
Study: 31533823
Drug: Weekly reminder
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly reminder e-mails
Study: 21055739
Drug: CDB-2914 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDB-2914 (20 mg)
Study: 21055739
Drug: CDB-2914 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDB-2914 (10 mg) and CDB-2914 (20 mg)
Study: 18204878
Drug: Durasphere anal
Normalized name: Mephitis mephitis anal gland fluid preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durasphere anal injection (mean of 8.8 ml injected)
Study: 17154744
Drug: Active high-dose
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active high-dose (35 mg) 24-hr patches
Study: 8515294
Drug: Ciprofloxacin plus
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin plus amoxicillin
Study: 9055918
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) therapy, 1 IU/kg/week, administered subcutaneously once daily
Study: 1841830
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (ivIgG) for prophylaxis of infection
Study: 1841830
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (ivIgG)
Study: 6357269
Drug: Stilboestrol therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stilboestrol therapy (mean dose of about 11.5 g starting at the 12th week of pregnancy)